Market News How it works Learn FAQ
| TGL 0.2897 30.79% | SRTM 0.6164 43.25% | NU 11.845 -21.87% | GCDT 0.1604 -8.92% | EWZ 31.98 -24.91% | NWGL 0.0808 -1.46% | SHFS 0.1254 -5.29% | RBNE 0.183 -3.68% | CLRO 4.2705 31.40% | SPRC 1.635 50.00% | SOXL 87.29 4.46% | BBD 2.9088 -28.53% | VBIO 0.785 -16.49% | RENT 2.85 23.91% | ITUB 7.63 -21.10% | PBR 21.675 -17.14% | SOXS 50.2 -4.31% | TSLL 10.68 9.43% | SPCX 147.12 -0.25% | XP 14.42 -52.58% | XXII 0.1032 -47.80% | GPUS 0.1583 -6.28% | WFF 0.0741 -7.38% | KORU 10.59 0.09% | CRWV 52.0841 -3.97% | IREN 24.13 -3.11% | STNE 7.83 -31.79% | SQQQ 39.02 -1.66% | PRSO 0.35 -7.51% | NOK 8.44 3.69% | INTR 4.751 -33.92% | MYND 0.2219 -7.54% | TQQQ 67.37 1.63% | INTC 88.11 1.32% | VALE 12.27 -1.05% | NVDA 214.88 1.86% | TSLA 389.99 4.77% | VZ 43.45 -2.71% | IBIT 44.9769 -2.14% | WORX 2.2101 0.92% | YMAT 2.25 9.76% | AZTR 0.9102 1,173.01% | JBLU 2.4312 -7.38% | STLA 4.105 1.11% | WULF 11.36 0.35% | T 21.075 0.69% | IRE 2.9 -6.15% | PAGS 8.6 -24.83% | META 631.35 -1.75% | NBIS 151.07 -4.83%
DMDamora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA)

NASDAQ Capital Market · Currency in USD
$21.41 ▲ +0.32 (+1.52%)
As of Oct 26, 9:46 AM ET. Market open.

Summary

Previous Close
$21.09
Open
$21.19
Day's Range
$21.12 – $21.48
52 Week Range
$4.95 – $38.33
Volume
4,039
Avg. Volume
622,390
Market Cap
$1.32B
Beta (5Y Monthly)
1.44
PE Ratio (TTM)
--
EPS (TTM)
-$4.30
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$52.50

Profile: Damora Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
7
CEO
Jennifer A. Jarrett

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.48
DateEst.Actual
Aug 11, 2026-$0.41-$0.39Beat
May 12, 2026-$0.21-$0.62Miss
Mar 18, 2026-$0.14-$3.24Miss
Nov 6, 2025-$0.10-$2.36Miss
Aug 5, 2025–-$2.60
May 8, 2025–-$1.92

Analyst view

Consensus price target
$52.50 ▲ +145.2%
Range $40.00 – $60.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on DMRA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.